MedTrace Logo

Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor

NCT07238712 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-11-20

No results posted yet for this study

Summary

Optimization of bendamustine-containg graft-versus-host disease (GVHD) prophylaxis to reduce the incidence of secondary haemophagocytic lymphohistiocytosis and GVHD

Conditions

  • Acute Myeloid Leukemia (AML)
  • Chronic Myeloid Leukemia
  • Myelodysplastic Syndromes (MDS)
  • Myeloprolipherative Neoplsm
  • Atypical Chronic Myeloid Leukemia

Interventions

DRUG

Ruxolitinib

; Days -1 through +21: ruxolitinib 10 mg/kg/day p.o.

DRUG

Abatacept (Orencia)

Days -1,+5, +14, +21 abatacept 10 mg/kg/day i.v.

Sponsors & Collaborators

  • St. Petersburg State Pavlov Medical University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-10
Primary Completion
2026-12-10
Completion
2026-12-10

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07238712 on ClinicalTrials.gov